{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:46:47Z","timestamp":1792457207309,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022110","name":"bioM\u00e9rieux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007229","name":"Harvard University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019428","name":"Nabriva Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017546","name":"Boston Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017639","name":"Entasis Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017639","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017787","name":"Health Science Center, University of North Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jgar.2021.04.012","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T12:39:15Z","timestamp":1622032755000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019)"],"prefix":"10.1016","volume":"26","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.04.012_bib0001","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jgar.2021.04.012_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12281-018-0306-0","article-title":"Challenges in the diagnosis of invasive fungal infections in immunocompromised hosts","volume":"12","author":"Antinori","year":"2018","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.jgar.2021.04.012_bib0003","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/fmb-2018-0059","article-title":"Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside","volume":"13","author":"Beardsley","year":"2018","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jgar.2021.04.012_bib0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0005","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S1473-3099(17)30304-3","article-title":"Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer","volume":"17","author":"Colombo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.idc.2015.10.004","article-title":"The global burden of fungal diseases","volume":"30","author":"Vallabhaneni","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.04.012_bib0007","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1093\/infdis\/jix179","article-title":"Antifungal resistance: an emerging reality and a global challenge","volume":"216","author":"Kontoyiannis","year":"2017","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.012_bib0008","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0009","series-title":"Methods in microbiology, Vol. 72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.mim.2015.05.002","article-title":"Invasive fungal infections and approaches to their diagnosis","author":"Pfaller","year":"2015"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.012_bib0010","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY Antifungal Surveillance Program: results for Candida species from 1997\u20132016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0011","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013","volume":"4","author":"Vallabhaneni","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00029-17","article-title":"Candida auris: a review of the literature","volume":"31","author":"Jeffery-Smith","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.04.012_bib0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ijantimicag.2017.05.012","article-title":"Molecular basis of antifungal drug resistance in yeasts","volume":"50","author":"Morio","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.012_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115007","article-title":"In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017\u20132018","volume":"97","author":"Messer","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof2040026","article-title":"New horizons in antifungal therapy","volume":"2","author":"Pianalto","year":"2016","journal-title":"J Fungi (Basel)"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.012_bib0016","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1093\/mmy\/myx113","article-title":"Scedosporium and Lomentospora: an updated overview of underrated opportunists","volume":"56","author":"Ramirez-Garcia","year":"2018","journal-title":"Med Mycol"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.04.012_bib0017","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/mmy\/myx101","article-title":"Challenges in the diagnosis and treatment of mucormycosis","volume":"56","author":"Skiada","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.jgar.2021.04.012_bib0018","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0019","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0020","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1128\/AAC.00366-11","article-title":"Efficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosis","volume":"55","author":"Hata","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0021","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.05414-11","article-title":"Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0022","doi-asserted-by":"crossref","first-page":"e02319","DOI":"10.1128\/AAC.02319-17","article-title":"In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris","volume":"62","author":"Hager","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0023","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/jac\/dkr342","article-title":"Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods","volume":"66","author":"Pfaller","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0024","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0026","doi-asserted-by":"crossref","first-page":"e00523","DOI":"10.1128\/AAC.00523-18","article-title":"In vitro and in vivo evaluation of APX001A\/APX001 and other Gwt1 inhibitors against Cryptococcus","volume":"62","author":"Shaw","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0027","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1128\/AAC.03944-14","article-title":"The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans","volume":"59","author":"Wiederhold","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01225-18","article-title":"APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method","volume":"62","author":"Arendrup","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00429-20","article-title":"Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs","volume":"64","author":"Arendrup","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0030","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001\u20132010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0031","doi-asserted-by":"crossref","first-page":"e01230","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0032","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011\u20132013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.04.012_bib0033","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.04.012_bib0034","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/j.1875-9114.2012.01124","article-title":"Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options","volume":"32","author":"Ashley","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2021.04.012_bib0035","doi-asserted-by":"crossref","first-page":"e01564","DOI":"10.1128\/JCM.01564-17","article-title":"Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern","volume":"56","author":"Astvad","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.04.012_bib0036","doi-asserted-by":"crossref","first-page":"e00906","DOI":"10.1128\/AAC.00906-17","article-title":"Monitoring antifungal resistance in a global collection of invasive yeasts and moulds: application of CLSI epidemiological cutoff values and whole genome sequencing analysis for detection of azole resistance in Candida albicans","volume":"61","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0037","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/JCM.44.3.693-699.2006","article-title":"Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions","volume":"44","author":"Leaw","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.04.012_bib0038","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance program","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"10.1016\/j.jgar.2021.04.012_bib0039","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00730-20","article-title":"In vitro activity of manogepix (APX001A) and comparators against contemporary moulds: MEC comparison and preliminary experience with colorimetric MIC determination","volume":"64","author":"J\u00f8rgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0040","series-title":"Performance standards for antifungal susceptibility testing of yeasts","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.012_bib0041","series-title":"Performance standards for antifungal susceptibility testing of filamentous fungi","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.012_bib0042","series-title":"EUCAST definitive document E.Def 7.3. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts","author":"Arendrup","year":"2015"},{"key":"10.1016\/j.jgar.2021.04.012_bib0043","series-title":"EUCAST definitive document E.Def 9.3. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds, version 9.3","author":"Arendrup","year":"2015"},{"key":"10.1016\/j.jgar.2021.04.012_bib0044","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","year":"2017"},{"key":"10.1016\/j.jgar.2021.04.012_bib0045","series-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","year":"2017"},{"key":"10.1016\/j.jgar.2021.04.012_bib0046","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2014.06.007","article-title":"Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections","volume":"44","author":"Castanheira","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.04.012_bib0047","series-title":"Epidemiological cutoff values for antifungal susceptibility testing","year":"2020"},{"key":"10.1016\/j.jgar.2021.04.012_bib0048","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/jof6040239","article-title":"Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections","volume":"6","author":"Shaw","year":"2020","journal-title":"J Fungi"},{"key":"10.1016\/j.jgar.2021.04.012_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00261-20","article-title":"Enhanced efflux pump expression in Candida mutants results in decreased manogepix susceptibility","volume":"64","author":"Liston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.04.012_bib0050","series-title":"Manual of clinical microbiology","first-page":"2334","article-title":"Mechanisms of resistance to antifungal agents","author":"Perlin","year":"2019"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:31Z","timestamp":1761991111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":50,"alternative-id":["S2213716521001119"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.012","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018\u20132019)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}